AZN•benzinga•
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal
Summary
Ionis grants Ono global rights to sapablursen for polycythemia vera in a deal worth up to $940M, including milestones and royalties on future sales.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 12, 2025 by benzinga